Mehra Ranee, Cohen Roger B
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi. doi: 10.1016/j.hoc.2008.08.010.
The treatment of relatively rare malignancies, such as those of the salivary glands and iodine refractory thyroid cancer, has been invigorated by the development of novel molecular targeting agents. Accrual to clinical trials for these disease sites continues to be limited by their relatively low incidence. Nonetheless, multicenter collaborations have contributed greatly to the development of a number of emerging systemic therapies. This article briefly summarizes the epidemiology and pathogenesis of salivary gland and thyroid cancer, and then describes some of the new drugs under evaluation for these malignancies.
新型分子靶向药物的发展为唾液腺肿瘤和碘难治性甲状腺癌等相对罕见恶性肿瘤的治疗注入了活力。这些疾病部位的临床试验入组人数仍然受到其相对较低发病率的限制。尽管如此，多中心合作对多种新兴全身治疗方法的发展做出了巨大贡献。本文简要概述了唾液腺和甲状腺癌的流行病学及发病机制，然后介绍了一些正在评估用于这些恶性肿瘤的新药。
